Discussion of “Power Priors for Leveraging Historical Data: Looking Back and Looking Forward”✩
Volume 23, Issue 1 (2025), pp. 38–47
Pub. online: 4 February 2025
Type: Discussion
Open Access
Open Access
✩
Main article: https://doi.org/10.6339/24-JDS1161.
Published
4 February 2025
4 February 2025
References
Ibrahim JG, Chen M-H (2000). Power prior distributions for regression models. Statistical Science, 15(1): 46–60. https://doi.org/10.1214/ss/1009212673
Chen M-H, Guan Z, Lin M, Sun M (2025). Power priors for leveraging historical data: looking back and looking forward. Journal of Data Science, 23(1): 1–30. https://doi.org/10.6339/24-JDS1161
Duan Y, Ye K, Smith EP (2006). Evaluating water quality using power priors to incorporate historical information. Environmetrics: The Official Journal of the International Environmetrics Society, 17(1): 95–106. https://doi.org/10.1002/env.752
Pawel S, Aust L, Held L, Wagenmakers E-J (2023). Normalized power priors always discount historical data. Stat, 12(1): e591. https://doi.org/10.1002/sta4.591
Schmidli H, Gsteiger S, Roychoudhury S, O’Hagan A, Spiegelhalter D, Neuenschwander B (2014). Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics, 70(4): 1023–1032. https://doi.org/10.1111/biom.12242
Izem R, Buenconsejo J, Davi R, Luan JJ, Tracy L, Gamalo M (2022). Real-world data as external controls: practical experience from notable marketing applications of new therapies. Therapeutic Innovation & Regulatory Science, 56(5): 704–716. https://doi.org/10.1007/s43441-022-00413-0
Lin J, Gamalo-Siebers M, Tiwari R (2022). Ensuring exchangeability in data-based priors for a bayesian analysis of clinical trials. Pharmaceutical Statistics, 21(2): 327–344. https://doi.org/10.1002/pst.2172
Job KM, Gamalo M, Ward RM (2019). Pediatric age groups and approach to studies. Therapeutic Innovation & Regulatory Science, 53(5): 584–589. https://doi.org/10.1177/2168479019856572
Gamalo M, Bucci-Rechtweg C, Nelson RM, Vanh L, Porcalla A, Thackray H, et al. (2022). Extrapolation as a default strategy in pediatric drug development. Therapeutic Innovation & Regulatory Science, 56(6): 883–894. https://doi.org/10.1007/s43441-021-00367-9
Gamalo MA, Tiwari RC, LaVange LM (2014). Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products. Pharmaceutical Statistics, 13(1): 25–40. https://doi.org/10.1002/pst.1588
